封面
市场调查报告书
商品编码
1527795

辅助生殖技术市场规模、份额、成长分析(按技术、按程序、最终用户、按地区)- 产业预测,2024-2031 年

Assisted Reproductive Technology Market Size, Share, Growth Analysis, By Technique(In Vitro Fertilization, Artificial Insemination, Frozen Embryo Transfer, Others), By Procedure, By End User, By Region - Industry Forecast 2024-2031

出版日期: | 出版商: SkyQuest | 英文 165 Pages | 商品交期: 3-5个工作天内

价格
简介目录

全球辅助生殖技术市场价值将从2023年的266.7亿美元增加至2022年的253亿美元,预测期内(2024-2031年)复合年增长率为5.40%,到2031年预计将达到70百万。

由于几个关键因素,全球辅助生殖技术(ART)市场正在见证显着成长。不孕率的上升、医疗技术的进步以及对 ART 治疗的认识和接受度的提高是这一扩张的主要原因。由于生活方式的改变、延迟怀孕、环境影响和各种医疗状况,越来越多的人寻求不孕不育治疗,从而增加了对体外受精(IVF)、显微授精(ICSI)和配子捐赠等ART手术的需求。采用延时成像系统和改进成分和稳定性的胚胎培养基等创新技术,显着提高了 ART 治疗的成功率。这些进步将有助于更好地监测和优化胚胎髮育,从而改善治疗结果。此外,对 ART 的日益接受也推动了市场的成长。从历史上看,围绕不孕症和辅助生殖技术的社会耻辱一直是其接受的障碍。然而,由于社会态度、教育努力和支持团体的变化,ART 现在被认为是面临不孕症挑战的夫妇的合法且有效的选择。这种日益增长的接受度导致更多的人接受不孕症治疗,增加了对 ART 服务的需求并进一步扩大了市场。

目录

介绍

  • 研究目的
  • 定义
  • 市场范围

调查方法

  • 资讯采购
  • 次要/一级资讯来源
  • 市场规模预测
  • 市场假设与限制

执行摘要

  • 市场概况展望
  • 供需趋势分析
  • 按细分市场的机会分析

市场动态及展望

  • 市场动态
    • 促进因素
    • 机会
    • 抑制因素
    • 任务
  • 波特的分析

主要市场考察

  • 技术分析
  • 案例研究分析
  • 市场生态系统
  • 监管环境
  • PESTEL分析
  • 创新矩阵
  • 重点投资分析
  • 关键成功因素
  • 市场魅力指数
  • 竞争程度

辅助生殖技术(ART)市场:依类型

  • 市场概况
  • 体外受精(IVF)
    • 新的捐赠者
    • 冷冻供体
    • 新鲜的非捐赠者
    • 冷冻非捐赠者
  • 人工授精
    • 子宫腔内人工授精
    • 子宫颈内人工授精
    • 阴道内人工授精
    • 输卵管内授精
  • 代孕

辅助生殖技术(ART)市场:依最终用途分类

  • 市场概况
  • 不孕不育治疗诊所
  • 医院
  • 专业艺术中心
  • 调查机构

辅助生殖技术 (ART) 市场规模:按地区

  • 市场概况
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 西班牙
    • 法国
    • 义大利
    • 英国
    • 其他欧洲国家地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地区
  • 中东和非洲 (MEA)
    • 海湾合作委员会国家
    • 南非
    • 其他中东/非洲地区

竞争格局

  • 前5名企业对比
  • 主要企业市场定位(2023年)
  • 主要市场参与者所采取的策略
  • 近期市集活动
  • 主要企业市场占有率(2023年)

主要企业简介

  • Vitrolife AB(Sweden)
  • CooperSurgical, Inc.(US)
  • Cook Medical, Inc.(US)
  • Irvine Scientific(US)
  • Genea Limited(Australia)
  • Ferring Pharmaceuticals(Switzerland)
  • Merck KGaA(Germany)
  • Thermo Fisher Scientific, Inc.(US)
  • Esco Group(Singapore)
  • Hamilton Thorne, Inc.(Canada)
  • Nidacon International AB(Sweden)
  • Kitazato Corporation(Japan)
  • OvaScience(US)
  • The Cooper Companies, Inc.(US)
  • IGENOMIX(Spain)
  • IVFtech ApS(Denmark)
  • Origio a/s(Denmark)
  • Cryolab Ltd.(United Kingdom)
  • Anecova(Switzerland)
  • Progyny, Inc.(US)
简介目录
Product Code: SQMIG35G2228

Global assisted reproductive market was valued at USD 25.30 billion in 2022 and is expected to rise from USD 26.67 billion in 2023 to reach a value of USD 40.67 billion by 2031, at a CAGR of 5.40% during the forecast period (2024-2031).

The global assisted reproductive technology (ART) market is experiencing notable growth, driven by several key factors. Rising infertility rates, advances in medical technology, and increasing awareness and acceptance of ART procedures are major contributors to this expansion. Changing lifestyles, delayed pregnancies, environmental influences, and various medical conditions are leading more individuals to seek fertility treatments, thereby boosting the demand for ART procedures such as in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and gamete donation. The introduction of innovative technologies, such as time-lapse imaging systems and improved embryo culture media with enhanced composition and stability, has significantly increased the success rates of ART procedures. These advancements help in better monitoring and optimizing embryo development, which in turn improves outcomes. Additionally, the growing acceptance of ART is fueling market growth. Historically, social stigma surrounding infertility and ART procedures created barriers to their use. However, shifting societal attitudes, along with educational initiatives and support groups, have helped normalize ART as a legitimate and effective option for couples facing infertility challenges. This increased acceptance has led to more individuals pursuing fertility treatments, thereby driving the demand for ART services and further expanding the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Assisted Reproductive market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Assisted Reproductive Market Segmental Analysis

The assisted reproductive technology (ART) market is segmented by type, application, and region. Based on type, the market can be segmented into in vitro fertilization (IVF) (fresh donor, frozen donor, fresh non-donor, frozen non-donor), artificial insemination (intrauterine insemination, intracervical insemination, intravaginal insemination, intratubal insemination) and surrogacy. Based on end use, the market is segmented into fertility clinics, hospitals, specialized ART centers, and research institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Assisted Reproductive Market

The global assisted reproductive technology (ART) market is expanding significantly due to rising infertility rates worldwide. Factors such as changing lifestyles, delayed pregnancies, and environmental influences contribute to the increasing demand for ART. These technologies provide solutions for individuals and couples facing fertility challenges, helping them achieve their goal of conceiving.

Restraints in the Global Assisted Reproductive Market

Ethical and legal concerns present significant challenges for the ART market, especially in certain regions. The application of ART procedures raises various ethical issues and is subject to diverse regulations. Key concerns include the appropriate disposal of embryos, the extent of donor anonymity, and the regulation of emerging techniques such as gamete and embryo editing. These issues can affect the availability and acceptance of specific ART procedures and, consequently, influence market dynamics.

Market Trends of the Global Assisted Reproductive Market

A notable trend in the global Assisted Reproductive Technology (ART) market is the rising demand for advanced genetic testing and screening technologies. As reproductive medicine progresses, there is an increasing focus on ensuring the health and viability of embryos before implantation. Techniques like preimplantation genetic screening (PGS) and preimplantation genetic diagnosis (PGD) are becoming more prominent as they help identify genetic abnormalities and chromosomal disorders in embryos. This trend is fueled by couples' desire for healthy children and growing awareness of how genetic testing can enhance the success rates of ART procedures.

Table of Contents

Introduction

  • Objectives of the Study
  • Definitions
  • Market Scope

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Market Overview Outlook
  • Supply Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers

Key Market Insights

  • Technology Analysis
  • Case Study Analysis
  • Ecosystem of the Market
  • Regulatory Landscape
  • PESTEL Analysis
  • Innovation Matrix
  • Top Investment Analysis
  • Key Success Factor
  • Market Attractive Index
  • Degree of Competition

Assisted Reproductive Technology (ART) Market by Type

  • Market Overview
  • In vitro fertilization (IVF)
    • Fresh Donor
    • Frozen Donor
    • Fresh non-Donor
    • Frozen non-Donor
  • Artificial Insemination
    • Intrauterine Insemination
    • Intracervical Insemination
    • Intravaginal Insemination
    • Intratubal Insemination
  • Surrogacy

Assisted Reproductive Technology (ART) Market by End Use

  • Market Overview
  • Fertility clinics
  • Hospitals
  • Specialized ART centers
  • Research institutes

Assisted Reproductive Technology (ART) Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • Italy
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2023
  • Strategies Adopted by Key Market Players
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2023

Key Company Profiles

  • Vitrolife AB (Sweden)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • CooperSurgical, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Cook Medical, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Irvine Scientific (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Genea Limited (Australia)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ferring Pharmaceuticals (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck KGaA (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Thermo Fisher Scientific, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Esco Group (Singapore)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Hamilton Thorne, Inc. (Canada)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Nidacon International AB (Sweden)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Kitazato Corporation (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • OvaScience (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • The Cooper Companies, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • IGENOMIX (Spain)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • IVFtech ApS (Denmark)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Origio a/s (Denmark)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Cryolab Ltd. (United Kingdom)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Anecova (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Progyny, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments